دورية أكاديمية

Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan

التفاصيل البيبلوغرافية
العنوان: Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
المؤلفون: Huang, Yen-Hsiang, Hsu, Kuo-Hsuan, Tseng, Jeng-Sen, Yang, Tsung-Ying, Chen, Kun-Chieh, Su, Kang-Yi, Yu, Sung-Liang, Chen, Jeremy J. W., Chang, Gee-Chen
المصدر: Targeted Oncology ; volume 18, issue 1, page 179-180 ; ISSN 1776-2596 1776-260X
بيانات النشر: Springer Science and Business Media LLC
سنة النشر: 2022
مصطلحات موضوعية: Pharmacology (medical), Cancer Research, Oncology
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1007/s11523-022-00928-4
DOI: 10.1007/s11523-022-00928-4.pdf
DOI: 10.1007/s11523-022-00928-4/fulltext.html
الإتاحة: https://doi.org/10.1007/s11523-022-00928-4Test
حقوق: https://creativecommons.org/licenses/by-nc/4.0Test ; https://creativecommons.org/licenses/by-nc/4.0Test
رقم الانضمام: edsbas.A45169E2
قاعدة البيانات: BASE